Expression of Programmed Death-Ligand 1 and Programmed Death-1 in Patients with Extramammary Paget's Disease | Zendy

Hiroyuki Goto | Zendy; Kazunari Sugita | Zendy; Osamu Yamamoto | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Expression of Programmed Death-Ligand 1 and Programmed Death-1 in Patients with Extramammary Paget's Disease

Author(s) -

Hiroyuki Goto,

Kazunari Sugita,

Osamu Yamamoto

Publication year - 2021

Publication title -

indian journal of dermatology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.395

H-Index - 36

eISSN - 1998-3611

pISSN - 0019-5154

DOI - 10.4103/ijd.ijd_341_18

Subject(s) - medicine , extramammary paget's disease , immunohistochemistry , paget disease , pd l1 , disease , cancer , immune system , pathology , antibody , oncology , cancer research , immunotherapy , immunology

Extramammary Paget's disease (EMPD) is a rare skin cancer and sometimes has fatal prognosis. For progressive cases, therapeutic options are limited. In recent years, treatment with an anti-programmed death-1 (PD-1) antibody has improved the prognosis of various malignancies. In addition, correlations between PD-ligand 1 (PD-L1) expression in tumor cells and favorable responses to anti-PD-1 therapy have been reported for several cancers. There have been a few case series of analysis of PD-L1 expression in patients with EMPD.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research